CN108367021A - 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 - Google Patents

包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 Download PDF

Info

Publication number
CN108367021A
CN108367021A CN201680073019.6A CN201680073019A CN108367021A CN 108367021 A CN108367021 A CN 108367021A CN 201680073019 A CN201680073019 A CN 201680073019A CN 108367021 A CN108367021 A CN 108367021A
Authority
CN
China
Prior art keywords
substituted
nucleic acid
acid sequence
unsubstituted
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073019.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·T·科尔蒂莱夫斯基
P·M·希维德尔斯基
G·马尔库奇
B·张
Y-H·郭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN108367021A publication Critical patent/CN108367021A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680073019.6A 2015-10-15 2016-10-14 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 Pending CN108367021A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242189P 2015-10-15 2015-10-15
US62/242,189 2015-10-15
PCT/US2016/057143 WO2017066639A1 (en) 2015-10-15 2016-10-14 Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Publications (1)

Publication Number Publication Date
CN108367021A true CN108367021A (zh) 2018-08-03

Family

ID=58517995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073019.6A Pending CN108367021A (zh) 2015-10-15 2016-10-14 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Country Status (6)

Country Link
US (4) US10801026B2 (https=)
EP (2) EP3985116A1 (https=)
JP (2) JP7038045B2 (https=)
CN (1) CN108367021A (https=)
CA (1) CA3001723A1 (https=)
WO (1) WO2017066639A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN108367021A (zh) 2015-10-15 2018-08-03 希望之城 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US12404509B2 (en) 2018-06-15 2025-09-02 City Of Hope Oligonucleotide-based proteolysis targeting chimera
US20220002730A1 (en) * 2018-08-24 2022-01-06 City Of Hope Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof
WO2020172198A1 (en) * 2019-02-18 2020-08-27 Duke University Prr-activating and microrna-inhibiting molecules and methods of using same
US11801266B2 (en) * 2019-03-05 2023-10-31 City Of Hope Methods of using anti-MIR126 compounds
WO2021108702A1 (en) * 2019-11-26 2021-06-03 City Of Hope Microrna as a therapeutic agent
US20250195666A1 (en) * 2021-05-20 2025-06-19 City Of Hope Mir-142 compounds and uses thereof

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116267A1 (en) * 2007-03-26 2008-10-02 Crc For Asthma And Airways Ltd Therapeutic targets and molecules
CN101448958A (zh) * 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
CN101472470A (zh) * 2006-04-24 2009-07-01 俄亥俄州立大学研究基金会 miR155转基因小鼠中前B细胞增殖和淋巴母细胞性白血病/高度淋巴瘤
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
WO2011011061A2 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
US20110077215A1 (en) * 2005-12-07 2011-03-31 The University Of Utah Research Foundation DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
CN102007408A (zh) * 2008-02-28 2011-04-06 俄亥俄州立大学研究基金会 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途
CN102186483A (zh) * 2008-08-11 2011-09-14 德克萨斯大学系统董事会 促进血管完整性的微rna及其用途
AU2011253959A1 (en) * 2004-05-28 2012-01-19 Asuragen, Inc. Methods and compositions involving MicroRNA
US20120065245A1 (en) * 2010-09-13 2012-03-15 California Institute Of Technology Regulation of hematopoietic stem cell functions through micrornas
US20120295963A1 (en) * 2007-03-07 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
WO2013040429A1 (en) * 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
US20130344135A1 (en) * 2012-06-21 2013-12-26 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US20140004154A1 (en) * 2010-12-16 2014-01-02 Steve Pascolo Pharmaceutical Composition Consisting Of RNA Having Alkali Metal As Counter Ion And Formulated With Dications
US20140377322A1 (en) * 2013-06-20 2014-12-25 Ajou University Industry-Academic Cooperation Foundation Multi-layered structure for drug reservoir and drug eluting stent including the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP1176966B1 (en) * 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
US20080214436A1 (en) * 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2010151640A2 (en) * 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
WO2011116152A2 (en) * 2010-03-16 2011-09-22 Sanford -Burnham Medical Research Institute Delivery of agents using interfering nanoparticles
US9796748B2 (en) * 2011-05-02 2017-10-24 President And Fellows Of Harvard College Spatial sequestration of dynamic nucleic acid circuits
RS54944B1 (sr) * 2012-07-12 2016-11-30 Proqr Therapeutics Ii Bv Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
EP2890402B1 (en) * 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
KR20220068276A (ko) * 2013-09-20 2022-05-25 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도
CN108367021A (zh) 2015-10-15 2018-08-03 希望之城 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011253959A1 (en) * 2004-05-28 2012-01-19 Asuragen, Inc. Methods and compositions involving MicroRNA
US20110077215A1 (en) * 2005-12-07 2011-03-31 The University Of Utah Research Foundation DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
CN101448958A (zh) * 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
CN101472470A (zh) * 2006-04-24 2009-07-01 俄亥俄州立大学研究基金会 miR155转基因小鼠中前B细胞增殖和淋巴母细胞性白血病/高度淋巴瘤
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
US20120295963A1 (en) * 2007-03-07 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
WO2008116267A1 (en) * 2007-03-26 2008-10-02 Crc For Asthma And Airways Ltd Therapeutic targets and molecules
CN102007408A (zh) * 2008-02-28 2011-04-06 俄亥俄州立大学研究基金会 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途
CN102186483A (zh) * 2008-08-11 2011-09-14 德克萨斯大学系统董事会 促进血管完整性的微rna及其用途
WO2011011061A2 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
US20120065245A1 (en) * 2010-09-13 2012-03-15 California Institute Of Technology Regulation of hematopoietic stem cell functions through micrornas
US20140004154A1 (en) * 2010-12-16 2014-01-02 Steve Pascolo Pharmaceutical Composition Consisting Of RNA Having Alkali Metal As Counter Ion And Formulated With Dications
WO2013040429A1 (en) * 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
US20130344135A1 (en) * 2012-06-21 2013-12-26 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US20140377322A1 (en) * 2013-06-20 2014-12-25 Ajou University Industry-Academic Cooperation Foundation Multi-layered structure for drug reservoir and drug eluting stent including the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KA LENNOX, ET AL.: "Chemical modification and design of anti-miRNA oligonucleotides", 《GENE THERAPY》, vol. 18, 14 July 2011 (2011-07-14), pages 1111 *
LEEUW, D C ET AL.: "Attenuation of microRNA-126 Expression That Drives CD34+38- Stem/Progenitor Cells in Acute Myeloid Leukemia Leads to Tumor Eradication", 《CANCER RESEARCH》, vol. 74, no. 7, 29 January 2014 (2014-01-29), pages 4 - 6 *
S ZIEGLER, ET AL.: "Bifunctional oligodeoxynucleotide/ antagomiR constructs: evaluation of a new tool for microRNA silencing", 《NUCLEIC ACID THERAPEUTICS》, vol. 23, no. 6, 11 December 2013 (2013-12-11), pages 427 - 434 *
ZIEGLER S, ET AL.: "Bifunctional oligodeoxynucleotide/ antagomiR constructs: evaluation of a new tool for microRNA silencing", 《NUCLEIC ACID THERAPEUTICS》, vol. 23, no. 6, 31 December 2013 (2013-12-31), pages 1 - 4 *
黄晓明 等: "人工microRNAs在肿瘤基因治疗中的研究", 中国细胞生物学学报, vol. 35, no. 07, 31 December 2013 (2013-12-31), pages 1018 - 1026 *

Also Published As

Publication number Publication date
JP7038045B2 (ja) 2022-03-17
JP2022081575A (ja) 2022-05-31
US12227745B2 (en) 2025-02-18
EP3985116A1 (en) 2022-04-20
US20180312837A1 (en) 2018-11-01
US20210115443A1 (en) 2021-04-22
JP2018530589A (ja) 2018-10-18
EP3364984B1 (en) 2021-11-17
US10801026B2 (en) 2020-10-13
US20250207135A1 (en) 2025-06-26
US20230340479A1 (en) 2023-10-26
EP3364984A4 (en) 2019-09-25
EP3364984A1 (en) 2018-08-29
US11591596B2 (en) 2023-02-28
WO2017066639A1 (en) 2017-04-20
CA3001723A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
US12227745B2 (en) Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US12611462B2 (en) Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US20240141362A1 (en) Modified oligonucleotides with increased stability
AU2019316640B2 (en) Modified oligonucleotides targeting SNPs
CA3172168A1 (en) Synthesis of modified oligonucleotides with increased stability
JP2020182472A (ja) 神経筋障害の治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
TWI816066B (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
JP2024514880A (ja) Ｐｎｐｌａ３発現を調節するための組成物及び方法
WO2022031237A1 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
JP2024502432A (ja) がん治療のための鋳型指向性免疫調節
CN112055597A (zh) 用于治疗胆管缺乏相关病况的方法和组合物
JP7208911B2 (ja) 核酸分子発現の調節
CN111615558A (zh) 用于调节erc1表达的寡核苷酸

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination